go-v.orgdoi

Pridopidine in the pharmacological treatment of Huntington’s disease

Martin Michl, Katharina Schnopfhagen, Raphael M. Bonelli · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.54
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

The available treatment options for Huntington’s disease (HD) are only symptomatic, partly with a limited symptom control and often accompanied by serious side effects. This review summarizes the current management of HD and elucidates why pridopidine might represent a turning point in the treatment of the condition. Pharmacology, clinical evidence, safety and tolerability of the drug will also be addressed. As pridopidine is a member of a new class of compounds, it opens up the field for new treatment strategies that might be more efficient in controlling motor symptoms, with fewer side effects than the treatment options currently available.

In a Phase II and III study, pridopidine significantly improved motor functions in Huntington patients with an adverse-event profile comparable to that of a placebo.

Open the resolved locator · 10.4155/cli.13.54

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:59 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.54
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.